SafriCanna

What SafriCanna does

SafriCanna (Pty) Ltd is a South African privately-held medicinal cannabis producer founded in 2014 and headquartered in Centurion, Gauteng. The company operates a fully-integrated cultivation, processing, and export business focused on pharmaceutical-grade EU-GMP certified cannabis, with end-to-end capabilities spanning GACP-compliant cultivation through to finished dried flower and extracts for international buyers. SafriCanna's facility is located at 152 London Lane, Knoppieslaagte, at 1,500m altitude with 280 sunny days per year, exploiting climatic and cost advantages relative to Northern Hemisphere producers. The company holds four regulatory credentials: SAHPRA GACP cultivation license (2020), SAHPRA Certificate of GMP for active pharmaceutical substances (2021), Control Union Medical Cannabis Standard (CUMCS) Version 4.0_2020 certification (2021), and EU GMP Part 1 certification from Bezirksregierung Düsseldorf (2023) — the first such certification granted to any African cannabis company.

SafriCanna's product portfolio comprises 16 medicinal cannabis strains, including both proprietary and globally recognized genetics such as Grape Galena, Karels Haze, GG4, Sour Diesel, and Mimosa. The go-to-market is a B2B enterprise sales model targeting international pharmaceutical manufacturers, distributors, and medical research institutions in regulated markets outside South Africa, with pricing conducted on a quote-based transactional basis and revenue generated via export shipments of EU-GMP certified cannabis ingredients. Distribution runs through direct enterprise relationships rather than third-party channels.

The company is privately held by its management team and undisclosed private investors, with no institutional venture capital, private equity, or debt financing specifically named in the disclosed data. The leadership team combines pharma and cannabis pedigree: the CFO is a chartered accountant (ICAEW and SAICA), the Responsible Pharmacist holds 35 years of pharmaceutical experience including a PhD-in-progress on cannabis from plant to finished product, and operational leaders are recruited from Canopy Growth, Fresenius Kabi, Cipla, and California-based Mattole CC. The company is positioned around regulatory certification as its primary moat, with the EU GMP Part 1 designation serving as both a barrier-to-entry for competing African producers and a credential for engaging European pharmaceutical buyers.

Name

SafriCanna

Legal name

SafriCanna (Pty) Ltd

Website

https://www.safricanna.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Short description

SafriCanna is a South African cannabis producer that cultivates, processes, and exports EU-GMP certified medicinal cannabis ingredients and strains to international pharmaceutical manufacturers, distributors, and medical research institutions through direct B2B export relationships.

Ownership category

akta.pro rank

Headquarters

HQ city

Centurion

HQ country

South Africa

HQ region

Africa

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Medicinal Cannabis Export: Revenue generated through export of EU-GMP certified medicinal cannabis products including dried flower, extracts, and pharmaceutical-grade cannabis ingredients to international pharmaceutical markets and distributors

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

SafriCanna cultivates, processes, and exports EU-GMP certified medicinal cannabis products (dried flower across 16 strains, extracts, and pharmaceutical-grade cannabis ingredients) to international pharmaceutical manufacturers, distributors, and research institutions. The company operates from a SAHPRA-licensed, EU GMP Part 1 certified facility in Centurion, South Africa, supplying pharmaceutical-grade active substances to regulated overseas markets.

Product overview

SafriCanna is a South African medicinal cannabis company focused on the growth, cultivation, processing, and export of EU-GMP certified medicinal cannabis products to international markets. The company operates as a fully-integrated medicinal cannabis brand, offering a portfolio of cannabis strains including Grape Galena, Dank Wafers, Vanilla Ice, Grapefruit Gift, Karels Haze, Creamy Kees, Black Cherry Punch, Miss Kim, Chem de la Chem, GG4, Sour Diesel, Double Dream, Hack Herer, Mimosa, Triangle Kush, and Coastal Sage. SafriCanna aims to serve the growing international cannabis market with A-grade medicinal cannabis products.

Differentiator

Problem solved

Functional benefit

Products and services

• Grape Galena medicinal cannabis flower strain

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Six partnerships are on record, tiered minor.

• BowmansminorOthersLaw firm partner visible in company logos section. Specific partnership details not provided.
• Green ZoneminorOthersPartner visible in company logos section. Specific partnership details not provided.
• CansativaminorOthersPartner visible in company logos section. Specific partnership details not provided.
• JJR IncminorOthersPartner visible in company logos section. Specific partnership details not provided.
• SM2minorOthersPartner visible in company logos section. Specific partnership details not provided.
• DeloitteminorOthersProfessional services partner visible in company logos section. Specific partnership details not provided.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Aurora Cannabis: Large Canadian licensed producer with established international medical cannabis operations, including EU-GMP certified facilities. Broad incumbent with similar B2B medicinal export ambitions.
• OrganiGram Holdings: Canadian licensed producer with international medical cannabis distribution and EU-focused supply. Broad incumbent comparable on medicinal export orientation, though at meaningfully larger scale.
• Canopy Growth Corporation: One of the largest global cannabis companies with significant international medical cannabis operations and pharmaceutical partnerships. Represents the incumbent scale player whose supply SafriCanna can complement or compete against in EU and emerging markets.
• Cronos Group: Canadian licensed producer with international medical cannabis operations, including European distribution. Broad incumbent whose medical division is most directly comparable to SafriCanna's export-led model.
• Tilray Brands: Global cannabis leader with pharmaceutical-grade production capabilities and established medical cannabis distribution across Europe and other regulated markets. Comparable as a broad incumbent with EU-GMP and international medical export reach.

Direct peers

• MediPharm Labs: Canadian GMP-certified producer focused on pharmaceutical-grade cannabis extracts and APIs supplied to international pharma and medical channels. Comparable to SafriCanna as a B2B, GMP-anchored supplier of medicinal cannabis inputs rather than consumer brands.
• Avextra: Germany-based EU-GMP certified medicinal cannabis company focused on the European pharmaceutical market. Directly comparable to SafriCanna on regulatory positioning (EU-GMP) and target buyer (European pharma).
• Clever Leaves: US-headquartered cannabis cultivator and EU-GMP certified processor exporting pharmaceutical-grade flower and extracts to international markets. Closest direct comparable to SafriCanna in business model (B2B EU-GMP certified medicinal cannabis, multi-country export focus).

Emerging players

• Panaxia Pharmaceutical Industries: Israeli pharmaceutical-grade cannabis producer with EU export focus and pharma-style operations. Comparable as a smaller, GMP-anchored, internationally-exporting medicinal cannabis company.
• Khiron Life Sciences: Latin American medical cannabis company pursuing EU-GMP certification and European market entry. Comparable emerging player with similar 'emerging-market origin, EU-GMP destination' model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/safricanna

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SafriCanna